Boehringer Ingelheim selects Veeva Development Cloud to accelerate the delivery of innovative therapies to patients worldwide

0 47

Boehringer Ingelheim and Veeva Systems on Tuesday announced that Boehringer Ingelheim has chosen Veeva Development Cloud to enable end-to-end procedures and seamless information exchange across the company, allowing for faster delivery of novel treatments. Boehringer Ingelheim, a leading research-driven biopharmaceutical firm, is developing innovative medications to better the lives of humans and animals while also creating value through innovation in high-unmet medical need areas. Boehringer Ingelheim will construct a connected technology landscape for agile collaboration that can speed the development of innovative medicines by bringing together data and processes across clinical, regulatory, and quality on a single cloud platform for the enterprise.

The transition is part of Boehringer Ingelheim’s Medicine Excellence program, which aims to create a ‘One Medicine Platform’ by bringing together development processes and data in a single location. Veeva’s technologies will aid in the realization of this ambition. Boehringer Ingelheim will streamline its IT infrastructure and create a more consistent user experience with Veeva Development Cloud, making it easier to access information and work cross-functionally.

“We believe in advancing health through partnerships and are excited to embark on this journey, strengthening our ability to create a positive impact on patient lives. Veeva Development Cloud will enable cross-functional teams to work more collaboratively and leverage data and insights, enhancing their ways of working,”

shared Uli Brödl, senior vice president, global clinical development and operations at Boehringer Ingelheim.

“Using Veeva’s next-generation clinical data management and operations applications in tandem with regulatory and quality will allow us to open borders between functions for continuous improvement. With unified data and processes, we can reduce complexity and develop an innovative, digital culture to better understand and solve medical needs,”

said Thomas Reith, senior vice president, head of IT research, development, and medicine at Boehringer Ingelheim. 

“Boehringer Ingelheim and Veeva have had an outstanding partnership for more than 10 years, starting in the commercial area. Our teams share a spirit of innovation, customer-centricity, and long-term thinking. We’re excited and honored to enter this next stage of our partnership,” 

said Peter Gassner, Veeva founder, and CEO.

“Boehringer Ingelheim is shaping the future of healthcare by embracing new ways of solving old challenges. We’re proud to be a trusted partner to advance R&D while empowering the company’s employees with data and an improved, familiar user experience throughout their business processes,”

concluded Rik Van Mol, senior vice president, Veeva Development Cloud.

Boehringer Ingelheim will use Vault CDMS, Vault CTMS, Vault eTMF, Vault Study Start-up, and Vault Payments as part of Veeva Development Cloud to speed up clinical development, streamline regulatory activities with Vault Registrations, Vault Submissions, Vault Submissions Publishing, and Vault Submissions Archive, and simplify quality processes with Vault QMS and Vault QualityDocs. The company will also begin its journey with the Veeva Digital Trials Platform, which will be used in conjunction with Veeva Site Connect to automate data flow with partner research sites.

Leave A Reply

Your email address will not be published.